添加提拉古或低剂量伊皮利穆到标准肝癌治疗并没有改善存活率和增加副作用. Adding tiragolumab or low-dose ipilimumab to standard liver cancer therapy didn’t improve survival and increased side effects.

在Atezolizumab和bevacizumab中添加tiragolumab没有改善未经治疗的高级肝细胞癌的无进展或总体存活率,根据在2025年ESMO大会上介绍的第3阶段试验。 Adding tiragolumab to atezolizumab and bevacizumab did not improve progression-free or overall survival in untreated advanced hepatocellular carcinoma, according to a phase 3 trial presented at the 2025 ESMO Congress. 这项涉及669名病人的研究发现,中位无进步存活率(8.2对8.3个月)和不成熟的总体存活数据没有带来重大好处。 The study, involving 669 patients, found no significant benefit in median progression-free survival (8.2 vs. 8.3 months) and immature overall survival data. 另外一项独立的第二期试验也显示,将低剂量伊皮利穆马布添加到阿特佐利祖马布-贝瓦西祖马布并没有改善结果,而严重的副作用增加. A separate phase 2 trial also showed that adding low-dose ipilimumab to atezolizumab-bevacizumab did not improve outcomes and increased severe side effects. 这些结果强化了目前Atezolizumab-bevacizumab、durvalumab-tremelimumab和nivolumab-ipiliumab等三胞胎的标准,其治疗选择以个别患者因素为指导。 These results reinforce the current standard of triplets like atezolizumab-bevacizumab, durvalumab-tremelimumab, and nivolumab-ipilimumab, with treatment choices guided by individual patient factors.